Anti-inflammatory and Atheroprotective Properties of Omega-3 Polyunsaturated Fatty Acids

Alexander V Sorokin1*, Zhi-Hong Yang2 and Alan T Remaley2

1Section of Inflammation and Cardiometabolic Disease, Cardio-Pulmonary Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, USA
2Lipoxygenase Metabolism Section, Cardio-Pulmonary Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, USA

Received date: October 04, 2016; Accepted date: November 11, 2016; Published date: November 15, 2016

Abstract

Atherosclerosis prevention and treatment remain of great concern in the field of cardiovascular medicine. Altering inflammatory component of atherogenesis has been hypothesized to be beneficial, and thus searching for new anti-inflammatory compounds for cardiovascular disease is warranted. Recent discovery of new lipid mediators, which are generated from essential omega-3 fatty acids, represent a promising new area of investigation. These bioactive compounds, termed specialized pro-resolving lipid mediators (SPMs), have immunomodulatory and potent resolution effects. Moreover, cyclooxygenases inhibitors, such as acetylsalicylic acid, besides blocking eicosanoids production also trigger the biosynthesis of specific epimers of these SPMs. However, it has not been determined whether aspirin interacts synergistically with omega-3 fatty acids to affect atherosclerosis. The described anti-inflammatory and atheroprotective mechanisms of omega-3 fatty acids and aspirin could help in improving the treatment not just for cardiovascular but some of other inflammatory conditions.

Keywords: Atherosclerosis; Inflammation; Omega-3 fatty acids; Aspirin

Abbreviations: COX: Cyclooxygenase; DHA: Docosahexaenonic Acid; EPA: Eicosa Pentaenoic Acid; HETE: Hydroxyeicosa Tetraenoic Acid; HPETE: Hydroperoxyeicosa Tetraenoic Acid; LOX: Lipoxigenase; LT: Leukotriene; PD: Protectin; PG: Prostaglandin; Rv: Resolvin; TX: Thromboxane.

Introduction

Chronic inflammation is a critical contributing factor to the development of atherosclerosis [1]. Although there are several ongoing trials to assess whether drugs that directly suppress inflammation [2,3], most of the drugs commonly used to treat dyslipidemia are anti-inflammatory, except perhaps for fish oil [4]. The beneficial effects of fish oil appear to be due to long-chain omega-3 polyunsaturated fatty acids (PUFA), namely eicosapentaenoic acid (EPA, C20:5 n-3) and docosahexaenoic acid (DHA, C22:6 n-3). Omega-3 PUFA reduce inflammation through multiple mechanisms, including partial replacement of pro-inflammatory omega-6 arachidonic acid (C20:4 n-6) in cell membranes, a shift in the balance of the eicosanoid production and subsequent downstream effects, and modulation of the production and gene expression of transcription factors and pro-inflammatory cytokines [5].

Aspirin is the only other agent that does have some anti-inflammatory properties and is commonly used in cardiovascular disease, because of its anti-thrombotic effect [6]. By irreversible inhibition of cyclooxygenase 1 (COX-1), aspirin blocks the production of pro-inflammatory lipid mediators from arachidonic acid, such as prostaglandins (PGs), thromboxanes (TXs) and prostacyclins. It is well known that these mechanisms of action made aspirin the most relevant antiplatelet pharmacological agent for preventing and treating cardiovascular diseases (CVD) [7]. Moreover, previous studies showed that omega-3 PUFAs can also affect aggregation by utilizing various pathways [8-10]. Accumulated evidences from in vivo studies on omega-3 PUFAs anti-thrombotic effects led to the hypothesis that combinatorial treatment with aspirin might increase inhibitory action on platelets and result in better CVD outcomes [11,12]. However, the main concern of applying this treatment strategy clinically was reported to be an extra bleeding possibly associated with high dose of PUFAs [13]. Bleeding risk assessment was accomplished in many clinical trials showing that different concentrations of omega-3 PUFAs are generally safe and can be applied along with aspirin [14-16]. Although, the proposed treatment strategy associated with beneficial anti-thrombotic effects, alternative combination of aspirin with omega-3 PUFAs is not present in the last official guidelines on coronary artery disease management [17]. In this short review, we comment on our recent paper [18] and related work by others on the combined effect of fish oil and aspirin in a mouse model of atherosclerosis, which suggests that the combination of these two relatively safe and inexpensive medications may be a useful approach for CVD prevention.

A recent major breakthrough in our understanding of inflammation has been the identification of lipid-mediators that resolve inflammation [19]. These potent specialized pro-resolving lipid mediators (SPMs) are produced locally at the sites of inflammation and are derived from omega-3 PUFAs enriched in fish oils, EPA and DHA [20]. Resolvins (Rv), protectins (PD) and maresins (Mar) are examples of anti-inflammatory molecules produced from omega-3 PUFAs (Figure 1) [21]. The synthesis of most of these pro-resolution lipid mediators are also dependent upon either cyclooxygenases (COX-1, COX-2) and lipoxygenases (5-LOX, 12-LOX, 15-LOX) and the presence of arachidonic acid and omega-3 PUFAs substrates. Moreover, COX-2 partial inhibition by acetylsalicylic acid (aspirin; ASA) is known to switch the enzymatic activity from a prostaglandin
endoperoxide synthase to a lipoxigenase that leads to the production of aspirin-triggered (AT) lipid mediators, which also has anti-inflammatory effects (Figure 1) [22]. We, therefore, tested the hypothesis that a combination of fish oils and aspirin may act synergistically in reducing inflammation in a mouse model of atherosclerosis [18].

In our study, apoE-null mice were put on the following purified customized diets: Omega-3 PUFA deficient (OD), Omega-3 PUFA Rich (OR) (1.8 g Omega-3 PUFAs/kg-diet per day), Omega-3 PUFA Rich plus ASA (ORA) (0.1 g ASA/kg diet per day), or an Omega-3 PUFA deficient plus ASA (ODA), with supplement levels equivalent to human doses. As we anticipated, mice on the ORA diet had lower tissue levels of arachidonic acid derived prostanoids compared to omega-3 PUFAs enriched diet alone [18]. Specifically, for prostaglandin D2 (PGD2), prostaglandin E2 (PGE2), prostaglandin F2α (PGF2α) and 15R-hydroxyeicosatetraenoic acid (15-HETE), the ORA group had lower values than either the ODA or OR groups. Moreover, only mice on the ORA diet had significantly reduced atherosclerosis compared to the OD and OR diet groups, as determined by en face analysis of the aorta. We also observed significantly lower serum proinflammatory cytokines concentration of mammalian keratinocyte chemoattractant (mKC) and monocyte chemoattractant protein-1 (MCP-1) in the OR and ORA diet groups. The other measured cytokines (IFN-γ, TNF-α, IL-1β, IL-6, IL-10 and IL-12p70) were not significantly differing between the groups.

![Figure 1: Biosynthesis of eicosanoids and specialized pro-resolving mediators.](image)

In support of our findings it has been shown by others that plasma level of aspirin-triggered lipoxin are significantly lower in patients with peripheral atherosclerosis than in healthy volunteers [23]. Another aspirin-triggered mediator, aspirin-triggered resolvin D3 (AT-RvD3), has also been described to have a protective action for injured mucosa and helps restore epithelial barrier and function [24]. Although, we did not measure AT-RvD3 in our experiment, the highest concentration of AT-RvD1 was detected in mice in the ORA diet. However, complete suppression of COX-2 and the corresponding reduction in prostaglandin production has been shown to enhance arterial stiffness in humans [25]. Patients with metabolic syndrome showed an increase in plasma E-series resolvins without any alteration in plasma SPMs after addition of aspirin [26]. Overall, these observations suggest that anti-inflammatory action of aspirin are determined not only by the inhibition of COXs but may also involve alternative SPMs pathway activation and perhaps the availability of omega-3 PUFAs [27]. Interestingly, patients with coronary artery disease are deficient in aspirin-triggered forms, such as AT-RvD3, AT-lipoxin B4 (AT-LXB4) and treatment of these patients with omega-3 PUFAs (Lovaza) restores these lipid mediators to normal levels [28]. Moreover, topical RvE1 application in rabbit model attenuates enhanced atherogenesis and inhibits vascular inflammation by stimulating resolution of inflammation [29]. A combination treatment with RvE1 and atorvastatin in mice also resulted in a more prominent reduction of atherosclerotic lesion area [30].

An unexpected finding from our study was the effect of the diets on proprotein convertase subtilisin/kexin type 9 (PCSK9). Both on the OR and ODA diets, we observed a significant reduction of PCSK9 hepatic mRNA levels and PCK9 protein in the plasma compared to the OD and ODA diets. Because we did not observe these changes on just the ODA diet, these changes are most likely due to the addition of fish oils to the diet. PCSK9 is known to bind to the LDL-receptor, leading to its degradation [31]. Recently, two monoclonal antibody therapies against PCSK9 have been approved for lowering LDL-C [32]. They have also been reported to significantly reduce plasma triglycerides (TG) levels [33] although, no significant lipid differences were observed among the diet groups in our study. These ambiguous results might be explained by different cholesterol composition in the applied diets. The diet used in the previous studies [34,35] contained significant levels of cholesterol (~2000 ppm), whereas we utilized a customized purified EPA+DHA-deficient diet with a relatively low cholesterol level (<40 ppm).

It will be important to extend our work in other animal models and to ultimately test the combination of fish oils and aspirin in a clinical trial. Furthermore, a greater understanding eicosanoid metabolism and the role of SPMs in catabasis of inflammation-associated diseases may lead to new insights for the treatment of other inflammatory diseases, such as asthma, rheumatoid arthritis, psoriasis, lupus, and periodontitis, which are known to also have a predisposition to atherosclerosis.

**Acknowledgement**

This study was supported by the National Heart, Lung and Blood Institute (NHLBI) Intramural Research Program.

**References**

1. Libby P (2002) Inflammation in atherosclerosis. Nature 420: 868-874.
2. Ridker PM (2016) Informative Neutral Studies Matter—Why the Targeting Inflammation With Salisate in Cardiovascular Disease (TINSAL-CVD) Trial Deserves Our Attention. JAMA Cardiol 4: 423-424.
3. Ridker PM (2011) Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 4: 597-605.
4. Calder PC (2015) Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. Biochim Biophys Acta 4: 489-484.
5. Simopoulos AP (2002) Omega-3 fatty acids and inflammation and autoimmune diseases. J Am Coll Nutr 21: 495-505.
6. Patrono C, Rocca B (2012) Aspirin and Other COX-1 inhibitors. Handb Exp Pharmacol : 137-164.
7. Guirguis-Blake JM (2016) Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Ann Intern Med 12: 804-813.

8. Croset M, Lagarde M (1986) In vitro incorporation and metabolism of icosapentaenoic and docosahexaenoic acids in human platelets--effect on aggregation. Thromb Haemost 1: 57-62.

9. Kramer HJ (1996) Fish oil fatty acids and human platelets: dose-dependent decrease in dienoic and increase in trienoic thromboxane generation. Biochem Pharmacol 8: 1211-1217.

10. de Roos B, Mavrommatis Y, Brouwer IA (2009) Long-chain n-3 polyunsaturated fatty acids: new insights into mechanisms relating to inflammation and coronary heart disease. Br J Pharmacol 2: 413-428.

11. Andriamampandry MD, Leray C, Freund M, Cazenave JP, Gachet C (1999) Antithrombotic effects of (n-3) polyunsaturated fatty acids in rat models of arterial and venous thrombosis. Thromb Res 93: 9-16.

12. Harker LA (1994) New antithrombotic strategies for resistant thrombotic processes. J Clin Pharmacol 34: 3-16.

13. McClaskey EM, Micheaels EL (2007) Subdural hematoma after a fall in an elderly patient taking high-dose omega-3 fatty acids with warfarin and aspirin: case report and review of the literature. Pharmacotherapy 1: 152-160.

14. Pryce R, Bernatis N, Davey AK (2016) The Use of Fish Oil with Warfarin Does Not Significantly Affect either the International Normalised Ratio or Incidence of Adverse Events in Patients with Atrial Fibrillation and Deep Vein Thrombosis: A Retrospective Study. Nutrients 8.

15. Gajos G (2010) Omega-3 Fatty Acids: A New Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: The OMEGA-PCI (OMEGA-3 Fatty Acids after PCI to Modify Responsiveness to Dual Antiplatelet Therapy) Study. J Am Coll Cardiol 16: 1671-1678.

16. Watson PD (2009) Comparison of bleeding complications with omega-3 fatty acids + aspirin + clopidogrel--versus--aspirin + clopidogrel in patients with cardiovascular disease. Am J Cardiol 8: 1052-1054.

17. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, et al. (2016) ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery.

18. Sorokin AV, Yang ZH, Vaisman BL, Thacker S, Yu ZX, et al. (2016) Addition of aspirin to a fish oil-rich diet decreases inflammation and atherosclerosis in ApoE-null mice. J Nutr Biochem 35: 58-65.

19. Zhang MJ, Spite M (2012) Resolvins: anti-inflammatory and proresolving mediators derived from omega-3 polyunsaturated fatty acids. Annu Rev Nutr 32: 203-227.

20. Dennis EA, Norris PC (2015) Eicosanoid storm in infection and inflammation. Nat Rev Immunol 15: 511-523.

21. Serhan CN (2007) Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol 25: 101-137.

22. Serhan CN, Chiang N, Dalli J, Levy BD (2014) Lipid mediators in the resolution of inflammation. Cold Spring Harb Perspect Biol 7: a016311.

23. Ho KJ (2010) Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. Am J Pathol 4: 2116-2123.

24. Colby JK, Abdulnour RE, Sham HP, Dalli J, Colas RA, et al. (2016) Resolvin D3 and Aspirin-Triggered Resolvin D3 Are Protective for Injured Epithelia. Am J Pathol 186: 1801-1813.

25. Liu F (2016) Distal vessel stiffening is an early and pivotal mechanobiological regulator of vascular remodeling and pulmonary hypertension. JCI Insight 8.

26. Barden AE (2015) Specialized proresolving lipid mediators in humans with the metabolic syndrome after n-3 fatty acids and aspirin. Am J Clin Nutr 6: 1357-1364.

27. Merched AJ (2008) Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J 10: 3595-3606.

28. Elajami TK (2016) Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling. FASEB J 8: 2792-2801.

29. Hasturk H, Abdallah R, Kantarci A, Nguyen D, Giordano N, et al. (2015) Resolvin E1 (RvE1) Attenuates Atherosclerotic Plaque Formation in Diet and Inflammation-Induced Atherogenesis. Arterioscler Thromb Vasc Biol 35: 1123-1133.

30. Salec K (2016) Resolvin E1 attenuates atherosclerosis in absence of cholesterol-lowering effects and on top of atorvastatin. Atherosclerosis 250: 158-165.

31. Norata GD (2016) Biology of proprotein convertase subtilisin/kexin 9: beyond low-density lipoprotein cholesterol lowering. Cardiovasc Res.

32. Elbitar S (2016) Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015). Expert Opin Ther Pat 1-16.

33. Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, et al. (2014) A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 370: 1809-1819.

34. Brown WV, Bays H, Harris W, Miller M (2011) Using omega-3 fatty acids in the practice of clinical lipidology. J Clin Lipidol 5: 424-433.

35. Matsuzomo M (2008) Orally administered eicosapentaenoic acid reduces and stabilizes atherosclerotic lesions in ApoE-deficient mice. Atherosclerosis 2: 524-533.